ClinicalTrials.gg
TerminatedNCT00269828PIONEERUpdated Nov 24, 2020

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

A Phase 3 interventional study of paclitaxel and paclitaxel poliglumex in NSCLC, sponsored by CTI BioPharma. Terminated at 143 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 24 under way, 5 of them phase 3. Paclitaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
11th of 203
600 · median 50
Started
2005
with 8 others
Phase 3
39 of 221
4 open now
Registered
76th of 221
by date

Among the 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment of the 203 interventional ones that give a count, is one of 9 that started in 2005, is one of 39 in phase 3, and was the 76th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle

Read the detailed description

See Summary

03

Conditions studied

  • NSCLC

Keywords

  • Non-small cell lung cancer
  • NSCLC
  • PS 2
  • female
  • chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female.
  2. - or cytologically-confirmed diagnosis of NSCLC.
  3. performance score of 2.
  4. Patients who meet one of the following criteria:

    • Stage IIIB who are not candidates for combined modality therapy (primary radiation therapy or surgery), or
    • Stage IV.
  5. Age greater than or equal to 18 years.
  6. Adequate bone marrow function
  7. Adequate renal function
  8. Adequate hepatic function
  9. Patients with known must have received standard antitumor treatment for their CNS metastases as defined by the site's institutional standards.
  10. Patients who have had major surgery must be fully recovered from the surgery.
  11. Ability to comply with the visit schedule and assessments required by the protocol.
  12. For patients of , commitment to use adequate .
  13. Signed approved , with understanding of study procedures.
  14. Agreement to begin study therapy within 8 calendar days after randomization.

Exclusion criteria

Exclusion Criteria:

  1. Any intolerance to poly-L-glutamic acid, Poloxamer 188, dibasic sodium phosphate, monobasic sodium phosphate (the of CT-2103).
  2. Evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell histology.
  3. Any prior systemic chemotherapy for the treatment of lung cancer. This includes systemic radiosensitizers used to treat and any biologic agent.
  4. Concurrent primary except for carcinoma in situ or non-melanoma skin cancer.
  5. Grade 2 or greater neuropathy.
  6. Evidence of significant unstable neurological symptoms within the 4 weeks before study randomization. (If unstable neurologic symptoms resulted from brain metastases, patient must meet inclusion criteria number 9).
  7. active infection for which active therapy is underway.
  8. therapy within 4 weeks before randomization, unless local requirements are more stringent.
  9. Unstable medical conditions including unstable angina or myocardial infarction within the past 6 months before randomization. Patients with evidence of cardiac conduction abnormalities are eligible if their cardiac status is stable.
  10. Pregnant women or nursing mothers.
  11. Any circumstance at the time of study entry that would preclude completion of the study or the required follow-up.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to compare the overall survival of female patients randomized to CT-2103 to that of female patients randomized to paclitaxel.

Secondary outcomes

  1. Secondary objectives are to compare the progression-free survival, response rate, disease control, clinical benefit, quality of life, and the safety and tolerability of the treatment arms.

07

Study locations

143 sites
  • Desert Oasis Cancer Center
    Casa Grande, Arizona 85222, United States
  • Arizona Hematology Oncology
    Tucson, Arizona 85704, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • Heritage Physician Group, Oncology
    Hot Springs, Arkansas 71913, United States
  • Pacific Cancer Medical Center, Inc
    Anaheim, California 92801, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • Providence St. Joseph Medical Center
    Burbank, California 91505, United States
  • Hematology/Oncology Group of Fresno, Inc
    Fresno, California 93720, United States
  • Comprehensive Cancer Center-Research Office
    Glendale, California 91204, United States
  • Loma Linda University Cancer Institute
    Loma Linda, California 92354, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Medical Oncology Care Associates
    Orange, California 92868, United States
  • The Cancer Research and Prevention Center
    Soquel, California 95073, United States
  • Bethesda Research Center
    Boynton Beach, Florida 33435, United States
  • Broward Oncology Associates
    Fort Lauderdale, Florida 33308, United States
  • Florida Wellcare
    Inverness, Florida 34452, United States
  • Cancer & Blood Disease Center
    Lecanto, Florida 34461, United States
  • Oncology-Hematology Associates of West Broward
    Tamarac, Florida 33321, United States
  • Hematology Oncology Speaclist
    Tampa, Florida 33607, United States
  • Joliet Oncology Hematology Associates, Ltd.
    Joliet, Illinois 60435, United States
  • Loyola University Health Systems
    Maywood, Illinois 60153, United States
  • Mid-Illinois HEM & ONC Assoc.
    Normal, Illinois 61761, United States
  • Northern Indiana Cancer Research Consortium
    South Bend, Indiana 46601, United States
  • Associated Physicians & Surgeons Clinic
    Terre Haute, Indiana 47804, United States
  • Kentucky Cancer Clinic
    Hazard, Kentucky 41701, United States
  • West Kentucky Hematology & Oncology Group, PSC
    Paducah, Kentucky 42003, United States
  • Cabrini Center for Cancer Care
    Alexandria, Louisiana 71301, United States
  • West Michigan Cancer Center
    Kalamazoo, Michigan 49007, United States
  • Oncology Care Associates, PLLC
    Saint Joseph, Michigan 49085, United States
  • Troy, Michigan 48085, United States
  • Hubert H. Humphrey Cancer Center
    Robbinsdale, Minnesota 55422, United States
  • St. Louis Cancer Care Center
    Chesterfield, Missouri 63017, United States
  • Columbia Comprehensive Cancer Care Clinics
    Columbia, Missouri 65201, United States
  • Bond Clinic
    Rolla, Missouri 65401, United States
  • Saint Louis University
    Saint Louis, Missouri 63110, United States
  • Washington University Siteman Cancer Center Pharmacy
    Saint Louis, Missouri 63110, United States
  • Montana Cancer Specialists
    Missoula, Montana 59802, United States
  • Sierra Nevada Oncology Care
    Carson City, Nevada 89100, United States
  • Essex Oncology of North Jersey, PA
    Belleville, New Jersey 07109, United States
  • Atlanta HEM ONC
    Manasquan, New Jersey 08736, United States
  • Oncology and Hematology Specialist, PA
    Mountain Lakes, New Jersey 07046, United States
  • San Juan Oncology Association
    Farmington, New Mexico 87401, United States
  • Our Lady of Mercy Medical Center
    Bronx, New York 10466, United States
  • Suny Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Cancer Treatment Services
    Corning, New York 14830, United States
  • Interlakes Foundation, Inc.
    Rochester, New York 14623, United States
  • Guthrie Clinic
    Sayre, New York 18840, United States
  • New York Medical Collegw
    Valhalla, New York 10595, United States
  • Alamance Cancer Center
    Burlington, North Carolina 27215, United States
  • UNC Chapel Hill Oncology Protocol Office
    Chapel Hill, North Carolina 27599, United States
  • Leo Jenkins Cancer Center
    Greenville, North Carolina 28734, United States
  • Northwestern Carolina Oncology & Hematology
    Hickory, North Carolina 28602, United States
  • St. Alexius Medical Center
    Bismarck, North Dakota 58501, United States
  • University of Cleveland
    Cleveland, Ohio 44106, United States
  • Metro Health Medical Center
    Cleveland, Ohio 44109, United States
  • The Cleveland Clinic Foundation, Taussig Cancer Center
    Cleveland, Ohio 44195, United States
  • Dayton Clinical Oncology Program
    Dayton, Ohio 45429, United States
  • Signal Point Hematology/Oncology, Inc.
    Middletown, Ohio 45042, United States
  • Charleston Hematology Oncology
    Charleston, South Carolina 29403, United States
  • The Family Cancer Center
    Collierville, Tennessee 38077, United States
  • Mary Crowley Medical Research Center
    Dallas, Texas 75201, United States
  • JPS Center for Cancer Care
    Fort Worth, Texas 76104, United States
  • Columbia Basin HEM/ONC
    Kennewick, Washington 99336, United States
  • Sanatorio Parque
    Rosario, Santa Fe S2000DSV, Argentina
  • CETEN
    Beunos Aires, B1874ACL, Argentina
  • Hospital Privado de Comunidad
    Buenos Aires, B7602CBM, Argentina
  • Hospital General de Agudos "Dr Teodoro Alvarez"
    Buenos Aires, C1406FWY, Argentina
  • Instituto Alexander Fleming
    Ciudad de Buenos Aires, C1426ANZ, Argentina
  • Instituto Oncologico de Cordoba - IONC
    Cordoba, X5000AA1, Argentina
  • LUCEN
    Cuidad Autonoma de Buenos Aires, C1405CUB, Argentina
  • ISIS Clinica Especializada
    Urquiza, 3022, Argentina
  • District Oncology Dispensary
    Plovdiv, 4000, Bulgaria
  • District Oncolodispensary with Impatient sector
    Rousse, 7002, Bulgaria
  • Military Medical Academy
    Sofia, 1606, Bulgaria
  • Regional Oncology Dispensary with Inpatient Secot-Sofia District
    Sogia, 1233, Bulgaria
  • Regional Oncology Dispensary with Inpatient Sector
    Varna, 9010, Bulgaria
  • University Mulitprofile Hospital for Active Treatment "Sveta Marina"
    Varna, 9010, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sveta Marina"
    Varna, 9010, Bulgaria
  • Regional Oncology Dispensary with Inpatient sector
    Veliko Tarnovo, 5000, Bulgaria
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Erzsebet Juhasz
    Budapest, 1529, Hungary
  • University of Debrecen, Pulmonology Clinic
    Debreen, 4032, Hungary
  • Hospital for Thoracic Diseases of Csongrad Country
    Deszk, 6772, Hungary
  • Pulmonology Institute of Veszprem County
    Farkasgyepu, 8582, Hungary
  • Hospital for Pulmonological Diseases of the Bekes County
    Gyula, 5703, Hungary
  • Hospital of the Chest Desease of the Hungarian Reformed Church
    Mosdos, 7257, Hungary
  • Karolina Hospital
    Mosonmagyarovar, 9200, Hungary
  • Barany County Hospital
    Pecs, 7623, Hungary
  • Erzsebet Hospital
    Sopron, 9400, Hungary
  • Sanatorium for Pulmonological Diseases
    Torokbalint, 2045, Hungary
  • Centenario Hospital Miguel Hidalgo
    Aguascalientes, Ags. 20230, Mexico
  • CIMA Chihuahua
    Chihuahua, Chih 31238, Mexico
  • Hospital General
    Durango, Dgo. 34079, Mexico
  • Instituto Estatal de Cancerologia "Dr. Arturo Beltran Ortega"
    Acapulco, Gro 39570, Mexico
  • Hospital Dr. Angel Leano
    Zapopan, Jalisco 45200, Mexico
  • Hospital Star Medica Morelina
    Morelia, Michoacan 58070, Mexico
  • Monterrey International Research Center
    Monterrey, N.l. 64020, Mexico
  • Centro Estatal de Canceologia
    Jalapa, Veracruz 31238, Mexico
  • Centro Anticanceroso de la Cruz Roja Mexicana de Merida
    Merida, Yucatan 9700, Mexico

Showing the first 100 of 143 sites across 11 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2005
First posted
Dec 26, 2005
Start
Dec 2005
Completion
Dec 2006
Last update
Nov 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Nov 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00269828
Lead sponsor
CTI BioPharma
Responsible party
Sponsor
First posted
Dec 26, 2005
Start date
Dec 2005
Completion
Dec 2006
Last update
Nov 24, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Paclitaxel poliglumex

Start the discussion